Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Healthy, Renal Insufficiency
Interventions: Selpercatinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Anaheim, California • Pleasanton, California • Tustin, California + 3 more

Conditions: Diabetes Mellitus
Interventions: Wearing a non-invasive glucose sensor; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy
Interventions: Midodrine HCl Tablets 5 mg, ProAmatine® Tablets 5 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: high fat meal; Other
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pharyngitis
Interventions: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo, Acetaminophen + placebo, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Parkinson's Disease
Interventions: fipamezole; Drug
Lead sponsor: Juvantia Pharma Ltd; Industry
Eligibility: 30 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 29
States / cities: Birmingham, Alabama • Northport, Alabama • Tucson, Arizona + 25 more

Conditions: Skin Toxicities
Interventions: Questionnaire; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain Perception, Phlebotomy
Interventions: 4% lidocaine gel application with sham microneedle device, Microneedle-facilitated lidocaine application; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Achalasia
Interventions: Barostat; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Atenolol 100mg Tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Chapell Hill, North Carolina

Conditions: Diabetes Mellitus, Type 1
Interventions: G-Pen Mini™ (glucagon injection), Glucose Tablets; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more

Conditions: Cough
Interventions: GSK5464714- Camlipixant; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteer
Interventions: S-888711, Calcium Antacid; Drug · Dietary Supplement
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: TAK-935 Tablets, TAK-935 Oral Solution; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Glendale, California

Conditions: Stroke
Interventions: NA-1, Placebo; Drug
Lead sponsor: NoNO Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 3
States / cities: Phoenix, Arizona • Stanford, California • Portland, Oregon

Conditions: Myelodysplastic Syndromes
Interventions: Oral rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 10
States / cities: Stanford, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Invasive Breast Carcinoma
Interventions: Short-Term Fasting, Chemotherapy, Biospecimen Collection, Questionnaire Administration; Other · Drug · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: Cherry Hill, New Jersey • Sewell, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Healthy
Interventions: tofacitinib modified-release (MR) formulation; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Endometrial Cancer
Interventions: Prolonged Overnight Fasting (POF), Blood Specimen Collection, Blood Sugar Monitor, Hysterectomy; Behavioral · Procedure · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Stroke
Interventions: Lifestyle Management Program, Post-stroke Optimization of Walking using Explosive Resistance; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 35 Years to 85 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 85
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: GRT6019; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Type 2 Diabetes
Interventions: Mitoglitazone, Pioglitazone, Placebo; Drug
Lead sponsor: Metabolic Solutions Development Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Huntsville, Alabama • Muscle Shoals, Alabama • Chino, California + 21 more

Conditions: Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions: Placebo, Colesevelam; Drug
Lead sponsor: Radiant Research; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more

Search by objective public record fields.

A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function

Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study

Fasting Study of Midodrine HCl Tablets 5 mg and ProAmatine® Tablets 5 mg

Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects

Evaluate the Time of Pain Relief of Fast Acting Aspirin Versus Acetaminophen in Subjects Diagnosed With Sore Throat Pain

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

Development of Dermatology-related Quality of Life Assessment in Patients Treated With Epidermal Growth Factor Receptor (EGFR) Inhibitors

Functional Microarray Augmentation of Skin Treatment With Lidocaine

Sensorimotor Dysfunction in Achalasia

Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions

Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants

Evaluating Neuroprotection in Aneurysm Coiling Therapy

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

Fasting InTervention for Endometrial Cancer

EMPOWER: Effects of Weight Loss and Exercise Post-stroke

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

A Trial to Investigate Safety and Pharmacokinetics of GRT6019, Including Food Effect, in Healthy Male Participants

Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy